Management Change/Compensation Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 15, 2024, MiNK Therapeutics, Inc. (the "Company") acknowledged that Dr. Marc Van Dijk will transition from his role as Chief Scientific Officer and assume the positions of Scientific Advisory Board Member and Strategic Consultant. This transition will be effective as of November 15, 2024. Dr. Van Dijk will continue to contribute his expertise in his new role, supporting the Company's programs and collaborations.